Medtech-INSIDE – Part 10: “Indispensable: Security in a digitalized medicine”
The use of IT and AI increases efficiency and quality of care in medicine – but also the vulnerability of the systems. How do we combine progress with security?
Current news of SHS and our portfolio companies
The use of IT and AI increases efficiency and quality of care in medicine – but also the vulnerability of the systems. How do we combine progress with security?
The Swiss company TRI Dental Implants Int. AG officially presented the matrix® implant system with its six patented product features at the hybrid event TRITalks in Zurich on 18 June 2021. matrix® does not require an abutment or cementation and thus represents a technical revolution in dental medicine. Key opinion leaders from various countries brought […]
SHS offers students from various disciplines the opportunity to complete an internship during their studies. In this way, SHS gives young, motivated people a practical insight into the areas of growth companies and private equity. SHS sees this as an important contribution to the professional development of future top performers. We were pleased to welcome […]
ESG investing in practice After explaining the topic in principle in Parts 1 and 2 of the series “ESG Investing” and showing how ESG investing is anchored throughout at SHS, today we describe two examples from the SHS portfolio. The “S” in the abbreviation ESG investing stands for “social”. This refers to social goals that […]
The world’s first jaw surgery with a bone incision using the CARLO® laser system from AOT was performed at the Paracelsus Clinic in Munich on 14 May 2021. Prof. Dr. Dr. med. Jürgens, who co-developed the robot-controlled laser surgical system, removed the bone layer by layer – without contact – using a laser during the […]
Surgical services are one of the major cost factors in everyday hospital life. Patients expect excellent results from surgery, and payers expect efficient interventions. It is no secret that there are sometimes considerable differences in quality from clinic to clinic. The Dutch company Incision, in which SHS has a stake, has set itself the goal […]
The high-tech company Crystal GmbH produces and processes diffusion-joined laser crystals, substrates for thin-film applications and optical components, among other things. In the field of crystal processing, Crystal is one of the leading suppliers and an important supplier to the medical technology industry. SHS invested in Crystal from its Fund II and is now handing […]
Dipl.-Ing. Marcus Raguse joined the management team of SHS portfolio company Novo Klinik-Service GmbH in May 2021. Novo offers medical aids and medical technology solutions. The graduate engineer brings with him a great deal of experience and know-how in the healthcare sector and, together with Ulrich Frick, who has been Managing Director since January 2021, […]
The company c-LEcta is one of the world’s leading biotech companies in the field of enzyme production. More than 200 customers in 40 countries, including well-known pharmaceutical companies, rely on the enzyme products from Leipzig. 2020 was a successful year for c-LEcta, in which the 10 million euro mark in turnover was broken for the […]
With the appointment of Dr. Alan Levy as Chairman of the Board, the Dutch growth company Salvia BioElectronics brings profound life science expertise and decades of experience to the team. Dr Levy has successfully exited four out of five early-stage healthcare companies and also sits on the board of Intuitive Surgical. Salvia develops electromedical neurostimulation […]
Dentist appointment 14,000 years ago Regular visits to the dentist are part of our natural health routines throughout the year, even if not every appointment in the dental chair is equally pleasant. But we should not complain, but feel privileged, as a look at the history of dentistry shows. It begins about 14,000 years ago […]
Afinum and SHS Capital have sold their stakes in Switzerland-based diagnostic and therapeutic antibodies specialist Evitria toSweden-based Atlas Antibodies in a deal that values Evitria atmore than EUR 200m.
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information